LeMaitre Vascular (NASDAQ:LMAT) Releases Q2 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its second quarter 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.790-0.840 for the period, compared to the consensus estimate of 0.760. The company issued revenue guidance of $70.5 million-$72.5 million, compared to the consensus revenue estimate of $71.5 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.930-3.080 EPS.

Analyst Ratings Changes

A number of brokerages have recently commented on LMAT. Weiss Ratings upgraded shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Barrington Research raised their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Finally, Citizens Jmp raised their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.80.

LeMaitre Vascular Trading Up 0.4%

Shares of LMAT traded up $0.47 during mid-day trading on Tuesday, hitting $112.00. The company had a trading volume of 225,462 shares, compared to its average volume of 173,958. The business’s 50-day simple moving average is $109.28 and its 200-day simple moving average is $94.17. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. LeMaitre Vascular has a 1-year low of $78.35 and a 1-year high of $118.01. The stock has a market cap of $2.56 billion, a PE ratio of 44.62, a P/E/G ratio of 3.21 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business had revenue of $66.55 million for the quarter, compared to analysts’ expectations of $66.67 million. During the same period last year, the company earned $0.48 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Sell-side analysts forecast that LeMaitre Vascular will post 2.89 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were paid a dividend of $0.25 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s payout ratio is 39.84%.

Insider Buying and Selling

In related news, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the sale, the director owned 17,979 shares in the company, valued at approximately $1,920,157.20. The trade was a 32.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 215,438 shares of company stock worth $23,062,911. Insiders own 7.40% of the company’s stock.

Key LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Earnings beat and year-over-year EPS growth — LMAT reported Q1 EPS of $0.68 vs. the Zacks consensus $0.66 and $0.48 a year ago, indicating margin strength and operating leverage. LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
• Positive Sentiment: Management raised EPS guidance — LMAT set Q2 2026 EPS guidance of $0.79–$0.84 (above consensus $0.76) and FY2026 EPS guidance of $2.93–$3.08 (above consensus ~$2.90), signaling confidence in demand and near-term profitability. View Press Release
• Positive Sentiment: Dividend declared — the company announced a quarterly cash dividend of $0.25/share, which supports income-focused investors and can be viewed as a sign of cash-generative business. LeMaitre Q1 2026 Financial Results
• Positive Sentiment: Strong profitability metrics — Q1 net margin (~23.1%) and ROE (~14.7%) underline efficient operations and support the elevated EPS outlook. View Press Release
• Neutral Sentiment: Revenue roughly in line with expectations — Q1 revenue was $66.55M versus consensus ~$66.67M, effectively in line; this tempers but does not negate the EPS beat. LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates
• Neutral Sentiment: Revenue guidance band roughly matches consensus — FY revenue guidance $277M–$283M brackets street estimates (~$279.5M), so upside is more EPS-driven than revenue-driven at this point. View Press Release
• Negative Sentiment: Minor revenue shortfall vs. consensus — Q1 revenue missed by about $0.12M (66.55M vs. 66.67M), which is immaterial in isolation but worth watching if the trend continues. View Press Release

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently added to or reduced their stakes in LMAT. EverSource Wealth Advisors LLC bought a new stake in LeMaitre Vascular during the second quarter valued at $47,000. Geneos Wealth Management Inc. increased its stake in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. Quarry LP increased its stake in LeMaitre Vascular by 267.2% during the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after purchasing an additional 529 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in LeMaitre Vascular during the fourth quarter valued at $68,000. Finally, Kemnay Advisory Services Inc. bought a new stake in LeMaitre Vascular during the fourth quarter valued at $80,000. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.